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Several studies have evaluated the clinical relevance
of  the  associat ion between mal ignancy and
hyperfunction of the thyroid gland. Thyroid cancer
has been reported in 0.21% to 9.0% of glands removed
in the treatment of hyperthyroid patients, depending
on the criteria used to select patients for surgery and
the patients’ characteristics [1–3]. This indicates that
the coexistence of hyperthyroidism and thyroid can-
cer should no longer be considered rare. Indeed, in
more recent series, the prevalence of malignancy in
hyperthyroid patients has tended to be even higher,
probably as a consequence of more detailed inves-
tigations [3–5]. To better understand the association of
thyroid cancer with hyperthyroidism, we retrospec-
tively reviewed the data of hyperthyroid patients who
had previously undergone surgery.
MATERIALS AND METHODS
All the medical records of 45 patients (34 females and
11 males; mean age at diagnosis, 32.4 years; range, 14–
67 years) who underwent surgery for hyperthyroidism
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The reported prevalence of thyroid cancer with concurrent hyperthyroidism varies from
0.21% to 9.0%. This variability may be due to multiple factors, such as indications for surgery
and histopathologic accuracy. However, this condition is not rare and its prevalence has
increased in recent surveys, perhaps as a result of more detailed examinations. The aim of
this retrospective study was to determine the prevalence of thyroid cancer in hyperthyroid
patients at surgery. Forty-five patients, 34 women and 11 men, underwent surgery for
hyperthyroidism in our department between 1989 and 2000. Ages ranged from 14 to 67 years.
There were 42 cases of Graves’ disease, one of functional multinodular goiter, and two of
single toxic nodules. Forty-three patients underwent total thyroidectomy and two underwent
total lobectomy. Six cases (13.3%) of thyroid cancer were found, two men and four women
with ages ranging from 19 to 48 years. Final histologic examination revealed three papillary
carcinomas, one follicular carcinoma, one follicular carcinoma combined with clear-cell
carcinoma, and one clear-cell carcinoma. Thus, in our department, the prevalence of thyroid
cancer in hyperthyroidism treated using surgery was 13.3%. Our study showed that even
a single toxic nodule may occur with concurrent thyroid cancer. Careful evaluation of such
patients is needed to exclude the presence of associated malignancy and to determine the
most appropriate therapeutic plan.
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in our department during a 12-year period (1989–
2000) were analyzed retrospectively. Clinical data and
preoperative serum concentrations of triiodothyronine
(T3), thyroxine (T4), and thyroid-stimulating hormone
(TSH) were recorded. All data on surgery, post-
operative complications and clinical outcomes were
analyzed.
Hyperthyroidism was diagnosed on the basis of
elevated T3, elevated T4, and low TSH concentrations
in combination with hyperthyroid clinical symptoms
and signs. Before administration of antithyroid
medications, mean serum T3 concentration was
350.8 ng/dL (range, 173.3–800 ng/dL), and that of T4
was 18.7 µg/dL (range, 14.1–39 µg/dL). Serum TSH
concentration was less than 0.1 µIU/mL in each patient.
The 45 patients could be classified into three major
groups: 42 (93.3%) had Graves’ disease, two (4.4%)
had toxic multinodular goiter, and one (2.2%) had
solitary hyperfunctioning adenoma.
Indications for surgery included clinical findings
such as severe disease with recurrence after medical
treatment, side effects of medication, large goiter,
clinical suspicion of malignancy, or patient preference.
Methimazole treatment was typically used prior to
surgery to achieve a euthyroid state. One patient had
received both antithyroid drugs and radioiodine, and
two had undergone previous thyroid surgery in an-
other hospital 15 and 20 years before relapse,
respectively.
Surgical terms predominantly consisted of subtotal
or total thyroidectomy to treat toxic, diffuse, and
multinodular goiters. Toxic adenomas that presented
as solitary thyroid nodules were treated using
lobectomy. Two patients who had previously
undergone partial thyroidectomy underwent a second
surgery to achieve total thyroidectomy. The diagnoses
were confirmed postoperatively by histopathologic
examination of the surgical specimens according to
World Health Organization criteria [6].
After surgery, all patients received T4 replacement
to avoid hypothyroidism. Follow-up ranged from
4 months to 168 months, with a mean of 54.6 months.
RESULTS
Of the 45 patients with hyperthyroidism, six (13.3%)
had thyroid cancer. Two patients were men and four
were women; mean age was 35.8 years (Table). Of
these patients, four had Graves’ disease, one had toxic
multinodular goiter, and one had toxic adenoma.
Thyroid ultrasound revealed calcification in two
patients with Graves’ disease. One patient with Graves’
disease had suspected papillary carcinoma from
Table. Thyroid cancer in hyperthyroidism
Patient Sex/Age T3 T4 TSH Diagnosis Preoperative comment Histopathology
(yr) (ng/dL) (µg/dL) (µIU/mL)
1 F/48 291.5 14.4 < 0.2 Graves’ disease Sonography & thyroid Follicular carcinoma
scan: calcification;
6.7 × 2 cm cold nodule
2 F/40 248.5 18.5 < 0.2 Toxic multi- – Occult papillary
nodular goiter carcinoma
3 F/19 204.8 15.3 < 0.2 Solitary hyper- Sonography & thyroid Papillary carcinoma
functioning scan: 5.0 × 3.3 cm hot arising in adenoma
adenoma nodule
4 M/41 101.7 < 2 8.1* Graves’ disease – Clear-cell carcinoma
5 M/33 619.6 27.3 < 1 Graves’ disease Sonography: calcification; Papillary carcinoma,
1.5 × 1.4 cm nodule blood vessel invasion
6 F/34 530.8 24.8 < 0.1 Graves’ disease Sonography: 1.6 × 1.0 cm Follicular carcinoma
nodule; FNA: suspected combined with
papillary-follicular clear-cell carcinoma,
carcinoma tracheal invasion
*Patient 4 had received medical treatment in another institution. T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-
stimulating hormone; F = female; M = male; FNA = fine-needle aspiration.
Thyroid cancer in hyperthyroidism
381Kaohsiung J Med Sci August 2003 • Vol 19 • No 8
preoperative fine-needle aspiration (FNA) cytology.
Of the six malignancies, three were papillary thyroid
carcinomas, one was a follicular carcinoma, one was a
follicular carcinoma combined with clear-cell
carcinoma, and one was a clear-cell carcinoma.
There was no peri- or postoperative mortality
among these six patients. Postoperative hemorrhage
developed in one patient (Patient 1). Unilateral
transient vocal cord paralysis was observed in one
patient (Patient 4) who completely recovered within 4
weeks. Another patient (Patient 5) had unilateral
permanent vocal cord paralysis.
Mean follow-up was 78.3 months (range, 30–168
months). All six patients were alive and apparently
free of residual disease at the time of writing.
DISCUSSION
Although Howard Means stated in 1937 that, “One
might almost say that thyrotoxicosis was insurance
against cancer of the thyroid” [7], it has since been
repeatedly shown that malignancy of the thyroid and
hyperthyroidism may coexist. However, the reported
incidence of thyroid cancer in hyperthyroid patients is
highly variable, ranging between 0.21% and 9.0%.
This wide range is probably due to genetic and
environmental factors, such as the amount of iodine
intake, the different criteria adopted for surgical
selection of patients, the extent of thyroidectomy, and
the accuracy of the histologic analysis of removed
thyroid tissue. In the present report, most tumors
were papillary, and autopsy data certainly indicate
that this is by no means a rare tumor; most lesions
were minimal. Therefore, we think that there is a true
a s s o c i a t i o n  b e t w e e n  t h y r o i d  c a n c e r  a n d
hyperthyroidism.
In recent years, reports have appeared on the
growing prevalence of thyroid cancer in hyperthyroid
patients, possibly because the increased use of total
thyroidectomy as the treatment of  choice in
hyperthyroid patients is likely to increase the
possibility of finding so-called occult carcinomas,
which occur in the general population with a
prevalence of 0.45% to 35.6%. In addition, occult
thyroid lesions may be revealed by sonography-guided
FNA biopsy, which is being increasingly used for
preoperative investigation of thyroid nodules, par-
ticularly those of smaller, pericentimetric size. Finally,
a thyroid nodule, particularly when solitary or
dominant, raises the possibility of malignancy.
In our study, 13.3% of patients had a coexisting
carcinoma, which is more than reported in other
studies. Several factors may explain the high incidence
of carcinoma in our study. First, the use of medical and
radioiodine therapy since the 1950s has caused a
progressive decline in the number of patients referred
for thyroidectomy. Thus, in recent years, patients with
Graves’ disease who undergo surgical treatment
constitute a select group with more serious forms of
the disease. Second, eight of our 42 Graves’ disease
patients had palpable nodules, and a striking increase
in the risk of carcinoma has been reported in patients
with Graves’ disease with palpable nodules, with
incidences of up to 22.2% to 45.8% in excised nodules,
compared to 2.9% in patients without a recognizable
thyroid nodule [8–10]. Third, in our series, occult
carcinoma was also detected in Patient 2, who under-
went near-total thyroidectomy.
Patients 1, 4, 5, and 6, who had Graves’ disease, had
coexisting thyroid cancer. Patient 1 underwent total
thyroidectomy after calcification in bilateral thyroid
lobes was detected by thyroid ultrasound, and a cold
nodule was also found. She was diagnosed with thyroid
follicular carcinoma by histology. Microscopic
examination of the resected specimen from Patient 4
revealed thyroid clear-cell carcinoma. In Patient 5,
thyroid ultrasound showed focally heterogeneous
hypoechoic nodules with calcification in the bilateral
enlarged lobes of the thyroid gland. Papillary
carcinoma with blood vessel invasion was diagnosed
by histology. Thyroid ultrasound in Patient 6 revealed
one hypoechoic nodule in the isthmus. FNA cytology
showed hypercellularity, sheets of follicular cells,
marked anisonucleosis, some of which had nucleoli,
some intranuclear inclusion bodies, and some papillary
formations, so papillary follicular carcinoma was
suspected. However, the pathology report revealed
the partial transformation of follicular carcinoma into
clear-cell carcinoma of the thyroid gland. The follicular
component of the carcinoma was seen invading the
trachea. In Patient 2, an occult papillary carcinoma
was detected among the toxic multinodular goiter
after histologic examination of the surgically removed
thyroid gland. In Patient 3, a thyroid scan revealed a
hot nodule in the right lobe, and a papillary carcinoma
was present inside the hyperfunctioning nodule on
histology (Figure).
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In rare instances, thyroid carcinoma was embed-
ded in or adjacent to the hyperfunctioning thyroid
adenoma, appearing as a cold area within the
autonomous lesion itself. This observation is clinically
relevant, as it indicates that not all cold areas inside a
hot nodule should be considered the result of tissue
necrosis or hemorrhage. Patient 3 presented with a
thyroid carcinoma in the context of a hot nodule, but
the thyroid scan failed to detect cold areas as the
maximum internal diameter of the malignant lesion
was below the detection limit of the technique.
Experimental data and clinical reports suggest that
TSH not only stimulates normal thyroid cell growth
and function but also the growth of thyroid tumors.
Although TSH concentrations are low in thyrotoxicosis,
it is possible that earlier stimulation of the thyroid
gland by TSH might have initiated or promoted
changes favorable to subsequent tumor development
before the toxic state supervened and suppressed TSH
concentrations. However, it is not clear whether T3 or
T4 influences the growth of normal thyroid or thyroid
tumors. In Graves’ disease, factors other than TSH
clearly support tumor growth and function [11,12].
Chronic abnormal stimulation of the thyroid gland by
thyroid-stimulating antibody (TSAb) may facilitate
the neoplastic transformation of thyrocytes in
individuals with a critical genetic background.
Abnormal and prolonged stimulation of thyroid
follicular cells, such as that by TSAb, may predispose
these cells to subsequent genetic defects affecting the
function of specific proto-oncogenes, such as the ret or
trk thyrosine kinase receptor oncogenes, and lead to
the development of papillary carcinoma. Oncogene
activation is likely to be an important factor and clearly
requires further evaluation in these circumstances.
Dietary factors are also relevant. In most reported
series of  thyroid tumors in association with
hyperthyroidism, the lesions have been papillary, and
papillary carcinoma is known to be associated with
increased intake of iodine [13,14].
Differentiated papillary and follicular carcinoma
have been reported as the most frequent carcinomas in
Graves’ disease [15]. Our findings agree with this: of
the six cases of cancer in our study, there were three
papillary thyroid carcinomas, one follicular carcinoma,
and one follicular carcinoma combined with clear-cell
carcinoma.
Some authors have stated that tumors found in asso-
ciation with hyperthyroidism may be more virulent
than tumors not associated with hyperthyroidism, as
judged by the presence of lymph node metastases,
distant metastatic disease, and even transformation to
undifferentiated carcinoma [9,15]. The reasons for this
increased aggressiveness are not clear, although it has
been suggested that TSAb probably represents a con-
tinual proliferation stimulus. On the other hand, Vini
et al reported that differentiated thyroid cancer found
incidentally at surgery for hyperthyroidism had a
good prognosis [16]. However, the tumor in most
patients with thyroid cancer and concurrent hyper-
thyroidism is 1 cm or smaller, and it is widely accepted
that small thyroid carcinomas are associated with
excellent prognoses [17]. In our study, no signs of
metastases or extrathyroidal invasion were observed
in five patients (but were observed in Patient 6). All
were alive with no evidence of malignancy at the time
of writing.
Figure. In Patient 3, histology shows: (A) a papillary lesion
(arrow) within an adenomatous nodule (hematoxylin & eosin, × 1);
and (B) cuboidal tumor cells with ground-glass, grooved nuclei
arranged in a papillary structure (hematoxylin & eosin, × 80).
A
B
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Clearly, it is vital for clinicians to be aware of the
possibility of malignancy prior to treatment of
hyperthyroidism. In the case of single toxic nodules, a
sonographic examination of the thyroid gland may
help to identify coexistent subcentimetric nodules that
could harbor occult carcinomas. In addition, there
must be a readiness to perform FNA cytology, if
possible, on hyperfunctioning nodules as well as
coexisting cold nodules. Conventional soft tissue
roentgenographs of the neck to evaluate thyroid gland
calcification can be of some value. Higashi et al reported
that typical fine calcification was seen in 60% of patients
with thyroid cancer in Graves’ goiters, and in most of
these, the calcification pattern was considered to be
diagnostic of carcinoma [18].
Total thyroidectomy is considered by many to be
the most appropriate treatment for the majority of
thyroid cancers, but such aggressive surgery is not
usually performed for hyperthyroidism, except
p e r h a p s  i n  s e l e c t e d  p a t i e n t s  w i t h  s e v e r e
hyperthyroidism, those with previous relapses after
nonsurgical treatment, gross multinodularity, young
patients with Graves’ disease, and those with
aggressive ophthalmopathy [19]. However, Vini et al
have demonstrated that most tumors found in
association with thyrotoxicosis are of the minimal
papillary type [16]. These lesions are certainly ade-
quately treated by less than total thyroidectomy; in
most instances, a unilateral lobectomy is sufficient.
These data suggest that surgery should continue to be
the mainstay of treatment for toxic nodular goiters of
both the multinodular and solitary varieties.
CONCLUSIONS
In our study, the prevalence of thyroid cancer in
hyperthyroidism treated by surgery was 13.3%. A
potential risk of malignancy exists not only in patients
with detectable cold nodules in the context of diffuse
toxic goiters, but also in patients with single toxic
nodules. The eventual occurrence of thyroid cancer in
association with hyperthyroidism should always be
kept in mind when making decisions on the most
appropriate therapeutic options.
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